August J. Salvado

Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn et al. · Journal of Clinical Oncology · 2005 · 331 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

Jörge E. Cortes, Hagop M. Kantarjian, Stuart L. Goldberg et al. · Journal of Clinical Oncology · 2009 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh et al. · Journal of Neuro-Oncology · 2007 · 108 citations

Medicine, Oncology, Pharmacology +14

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders

Jörge E. Cortes, Francis J. Giles, Susan O’Brien et al. · Cancer · 2003 · 104 citations · Full text

Medicine, Hematology, Pharmacology +16

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

David A. Reardon, Merrill J. Egorin, Annick Desjardins et al. · Cancer · 2009 · 92 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17